US 12,570,728 B2Granted

Combinations of antibodies and bispecific antibodies comprising antigen-binding specifically recognizing Pseudomonas PcrV and Psl

AssigneeBeijing Solobio Genetechnology Company Ltd.

InventorsZhong Li, Maorong Yu

Life of this patent

Estimating the term…

Abstract

Provided are bispecific antibodies that specifically recognize PcrV and/or Psl from Pseudomonas aeruginosa, pharmaceutical compositions comprising antibodies specifically recognizing non-overlapping epitopes of Pseudomonas PcrV and/or Psl. Also provided are methods of making and using these antibodies.

Claims13

Dependent claims

A bispecific molecule comprising a first antigen-binding domain specifically recognizing Pseudomonas PcrV, and a second antigen-binding domain specifically recognizing Pseudomonas Psl, wherein the first antigen-binding domain comprises:

(a) a heavy chain variable domain (VH) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising DX1X2MS (SEQ ID NO:
20), wherein X1 is N or Y, and X2 is Y, H or P;
an HC-CDR2 comprising X1ISESGGSTNYADSVKG (SEQ ID NO:
15), wherein X1 is V or G;
and an HC-CDR3 comprising GRFSTX1SX2HFX3RAVYGMDV (SEQ ID NO:
21), wherein X1 is L, S, N or D, X2 is S or A, X3 is F or Y;
and a light chain variable domain (VL) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RASQGISSYLA (SEQ ID NO:
10);
an LC-CDR2 comprising AASTLQS (SEQ ID NO:
11), and an LC-CDR3 comprising QQLSSYPLX1 (SEQ ID NO:
19), wherein X1 is S or T;
or
(b) a VH comprising a HC-CDR1 comprising SYWMH (SEQ ID NO:
22);
an HC-CDR2 comprising RINEX1EX2SISYADSVKG (SEQ ID NO:
44), wherein X1 is D or N, and X2 is T, G or R;
and an HC-CDR3 comprising DGPYDX1X2DI (SEQ ID NO:
45), wherein X1 is S, A, or T, and X2 is F or L;
and a VL comprising an LC-CDR1 comprising RASQX1VX2X3NLA (SEQ ID NO:
46), wherein X1 is S, G or N, X2 is S, R or K and X3 is S or N;
an LC-CDR2 comprising X1ASSRAT (SEQ ID NO:
42), wherein X1 is D or H, and an LC-CDR3 comprising QQYGX1X2PX3T (SEQ ID NO:
47), wherein X1 is S, L or N, X2 is S, Q or E and X3 is L or I;
or wherein the first antigen-binding domain comprises:
(i) a VH comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
4, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
6;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
10, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
11, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
12;
or
(ii) a VH comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:
2, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
5, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
7;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
10, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
11, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
13;
or
(iii) a VH comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:
22, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
23, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
26;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
30, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
33, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
35;
or
(iv) a VH comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:
22, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
24, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
27;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
31, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
34, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
36;
and
wherein the second antigen-binding domain comprises:
(a) a VH comprising a HC-CDR1 comprising SSGDYWG (SEQ ID NO:
48);
an HC-CDR2 comprising SIHNX1GSTYYNPSLKG (SEQ ID NO:
81), wherein X1 is S or Q;
and an HC-CDR3 comprising QFGSETYYX1GIX2P (SEQ ID NO:
82), wherein X1 is T, N or P, and X2 is D or Q;
and a VL comprising an LC-CDR1 comprising RSSQSLLHSX1GYNYLD (SEQ ID NO:
83), wherein X1 is N or R;
an LC-CDR2 comprising LGSNRAS (SEQ ID NO:
70), and an LC-CDR3 comprising MQALQTPYT (SEQ ID NO:
74);
or
(b) a VH comprising an HC-CDR1 comprising IHSVH (SEQ ID NO:
50);
an HC-CDR2 comprising TIISSGTTTTYAQSFQD (SEQ ID NO:
55);
and an HC-CDR3 comprising DGX1S (SEQ ID NO:
84), wherein X1 is D or T;
and a VL comprising an LC-CDR1 comprising RASQGISSWLA (SEQ ID NO:
68);
an LC-CDR2 comprising HASTLES (SEQ ID NO:
72), and an LC-CDR3 comprising LQAX1SLPHT (SEQ ID NO:
85), wherein X1 is N, F, S or K;
or
(c) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
49, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
54, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
61;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
67, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
71, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
75;
or
(d) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
51, an HC-CDR2 comprising the amino acid sequence of SEQ ID NOs 56, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
64;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
69, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
73, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
80;
or wherein the second antigen-binding domain comprises:
(i) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
48, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
52, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
57;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
65, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
70, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
74;
or
(ii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
50, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
55, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
68, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
72, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
76.

124 more elements

Dependencies are inferred from the claim text.

Facts

Application: 18/036,949Filed 18 Nov 2021
Priority: WO PCT/CN2020/12967518 Nov 2020
Published: US 2024/0002482 A14 Jan 2024
Granted: 10 Mar 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
C07K 16/1214
Gram-negative bacteria: pseudomonadaceae
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies

Family

US 2024/0002482 A1Pre-grant publication · published 4 Jan 2024
US 12,570,728 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

(a) a heavy chain variable domain (VH) comprising a heavy chain complementarity determining region (HC-CDR) 1 comprising DX1X2MS (SEQ ID NO:
20), wherein X1 is N or Y, and X2 is Y, H or P;
an HC-CDR2 comprising X1ISESGGSTNYADSVKG (SEQ ID NO:
15), wherein X1 is V or G;
and an HC-CDR3 comprising GRFSTX1SX2HFX3RAVYGMDV (SEQ ID NO:
21), wherein X1 is L, S, N or D, X2 is S or A, X3 is F or Y;
and a light chain variable domain (VL) comprising a light chain complementarity determining region (LC-CDR) 1 comprising RASQGISSYLA (SEQ ID NO:
10);
an LC-CDR2 comprising AASTLQS (SEQ ID NO:
11), and an LC-CDR3 comprising QQLSSYPLX1 (SEQ ID NO:
19), wherein X1 is S or T;
or
(b) a VH comprising a HC-CDR1 comprising SYWMH (SEQ ID NO:
22);
an HC-CDR2 comprising RINEX1EX2SISYADSVKG (SEQ ID NO:
44), wherein X1 is D or N, and X2 is T, G or R;
and an HC-CDR3 comprising DGPYDX1X2DI (SEQ ID NO:
45), wherein X1 is S, A, or T, and X2 is F or L;
and a VL comprising an LC-CDR1 comprising RASQX1VX2X3NLA (SEQ ID NO:
46), wherein X1 is S, G or N, X2 is S, R or K and X3 is S or N;
an LC-CDR2 comprising X1ASSRAT (SEQ ID NO:
42), wherein X1 is D or H, and an LC-CDR3 comprising QQYGX1X2PX3T (SEQ ID NO:
47), wherein X1 is S, L or N, X2 is S, Q or E and X3 is L or I;
or wherein the first antigen-binding domain comprises:
(i) a VH comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:
1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
4, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
6;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
10, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
11, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
12;
or
(ii) a VH comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:
2, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
5, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
7;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
10, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
11, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
13;
or
(iii) a VH comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:
22, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
23, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
26;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
30, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
33, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
35;
or
(iv) a VH comprising an HC-CDR1 comprising the amino acid sequence SEQ ID NO:
22, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
24, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
27;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
31, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
34, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
36;
and
wherein the second antigen-binding domain comprises:
(a) a VH comprising a HC-CDR1 comprising SSGDYWG (SEQ ID NO:
48);
an HC-CDR2 comprising SIHNX1GSTYYNPSLKG (SEQ ID NO:
81), wherein X1 is S or Q;
and an HC-CDR3 comprising QFGSETYYX1GIX2P (SEQ ID NO:
82), wherein X1 is T, N or P, and X2 is D or Q;
and a VL comprising an LC-CDR1 comprising RSSQSLLHSX1GYNYLD (SEQ ID NO:
83), wherein X1 is N or R;
an LC-CDR2 comprising LGSNRAS (SEQ ID NO:
70), and an LC-CDR3 comprising MQALQTPYT (SEQ ID NO:
74);
or
(b) a VH comprising an HC-CDR1 comprising IHSVH (SEQ ID NO:
50);
an HC-CDR2 comprising TIISSGTTTTYAQSFQD (SEQ ID NO:
55);
and an HC-CDR3 comprising DGX1S (SEQ ID NO:
84), wherein X1 is D or T;
and a VL comprising an LC-CDR1 comprising RASQGISSWLA (SEQ ID NO:
68);
an LC-CDR2 comprising HASTLES (SEQ ID NO:
72), and an LC-CDR3 comprising LQAX1SLPHT (SEQ ID NO:
85), wherein X1 is N, F, S or K;
or
(c) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
49, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
54, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
61;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
67, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
71, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
75;
or
(d) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
51, an HC-CDR2 comprising the amino acid sequence of SEQ ID NOs 56, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
64;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
69, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
73, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
80;
or wherein the second antigen-binding domain comprises:
(i) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
48, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
52, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
57;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
65, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
70, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
74;
or
(ii) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO:
50, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO:
55, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO:
62;
and a VL comprising:
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO:
68, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO:
72, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO:
76.

124 more elements

Facts

Application

18/036,949Filed 18 Nov 2021

Priority

WO PCT/CN2020/12967518 Nov 2020

Published

US 2024/0002482 A14 Jan 2024

Granted

10 Mar 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
C07K 16/1214
Gram-negative bacteria: pseudomonadaceae
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies